Shire's Baxalta Acquisition: An Orphan Drug Market Dream?

After a long list of mergers and acquisitions in healthcare, what does Shire’s acquisition of Baxalta mean for the industry? Research suggests approximately 95% of the estimated 6,000+ rare diseases are yet to have a single FDA-approved drug treatment. However, this could be a thing of the past, going by the [...]